Camptothecin derivatives as chemoradiosensitizing agents
US8563537B2 · kind B2 · utility
0Cited by
58References
66Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Jul 29, 2008 |
| Grant date | Oct 22, 2013 |
| Priority date | — |
| Expiry date | Aug 17, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.